NCT01867320View on ClinicalTrials.gov

Raltegravir for HAM/TSP

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 5, 2013

Primary Completion Date

September 25, 2018

Study Completion Date

September 25, 2018

Conditions
HTLV-I Infection
Interventions
DRUG

Raltegravir

Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT01867320 - Raltegravir for HAM/TSP | Biotech Hunter | Biotech Hunter